top of page
Portfolio
Remedium Bio
Remedium Bio is bringing the curative potential of genetic medicine to large unmet needs, affecting how we live and age through application of our first-in-class Prometheus™ adjustable-dose gene therapy platform.
SENISCA
SENISCA has identified a new, druggable molecular cause of cellular ageing (senescence): RNA splicing dysregulation. The Company is developing oligonucleotide senotherapeutics that target splicing regulation, resulting in cellular reprogramming and disease modification by attenuating senescence.
bottom of page